Details for New Drug Application (NDA): 215422
✉ Email this page to a colleague
The generic ingredient in LYVISPAH is baclofen. There are twenty-one drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the baclofen profile page.
Pharmacology for NDA: 215422
Mechanism of Action | GABA A Agonists GABA B Agonists |
Medical Subject Heading (MeSH) Categories for 215422
Suppliers and Packaging for NDA: 215422
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LYVISPAH | baclofen | GRANULES;ORAL | 215422 | NDA | Amneal Pharmaceuticals LLC | 64896-076 | 64896-076-09 | 90 PACKET in 1 CARTON (64896-076-09) / 1 GRANULE in 1 PACKET |
LYVISPAH | baclofen | GRANULES;ORAL | 215422 | NDA | Amneal Pharmaceuticals LLC | 64896-077 | 64896-077-09 | 90 PACKET in 1 CARTON (64896-077-09) / 1 GRANULE in 1 PACKET |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULES;ORAL | Strength | 5MG/PACKET | ||||
Approval Date: | Nov 22, 2021 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Subscribe | Patent Expiration: | Jul 29, 2039 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | METHOD FOR TREATING SPASTICITY | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Sep 29, 2041 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Sep 29, 2041 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES |
Complete Access Available with Subscription